Vaxess Technologies

08/16/2023

Vaxess is thrilled to announce that it’s been recognized on the 2023 Impact/100, an annual list of the world’s most promising impact startups, compiled by Norrsken and its nomination partners.

More than 1.5 million people globally die each year from diseases for which there is a safe and effective vaccine. When you look at why many people remain unvaccinated, three of the main causes are that vaccines are inaccessible, people have needle-phobia, or people are too busy to prioritize a trip to a clinic to receive a vaccine. Vaxess’s vaccine patches have the potential to solve each of these three challenges, while also improving vaccine efficacy compared to an injection via needle and syringe.

Learn more about Vaxess, and all of the incredible companies on the 2023 Impact/100, below:
https://www.norrsken.org/impact100

11/02/2022

Vaxess is thrilled to announce $27 million in Series B funding! RA Capital Management led the round, with additional investors including MIT’s The Engine, Mission BioCapital, and Global Health Investment Corporation.

With this funding, Vaxess will continue to work towards commercializing the company’s shelf-stable, sustained-release vaccine patch. Instead of going to a pharmacy or doctor’s office to receive a vaccine via needle and syringe, Vaxess envisions a future in which you’ll have a vaccine patch mailed right to your door.

Read more about today’s funding announcement in The Boston Globe below!

Vaxess, a Cambridge startup with ties to Harvard, MIT, and Tufts, raised $27 million to test its technology in clinical trials after developing the idea for more than a decade.

08/03/2022

Vaxess is excited to announce we have entered a phase 1 clinical trial for the MIMIX™ Smart Release Patch! The trial will focus on administering a H1 influenza vaccine using our unique, silk-based vaccine patch. The trial takes us one step closer in our journey to ease the distribution and administration of vaccines, and ultimately redefine what is possible for home healthcare.

Read the full announcement here:

06/28/2022

Vaxess CEO, Michael Schrader, sat down with BiopharmaTrend.com to discuss our novel silk-based vaccine and therapeutic delivery technology and the future of home healthcare.

Read the full article below:

Ancient Material Promises To Solve Drug Delivery “Pain” by Andrii Buvailo Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com. Contributors are fully responsible for assuring they own any required copyright for any...

03/01/2022

Exciting times at Vaxess with many new additions to the executive team and a brand new headquarters to house the continually expanding company!

Read the full release here:

Vaxess Technologies, Inc., an innovative life sciences company developing a pipeline of shelf-stable and simple-to-apply vaccines on the MIMIX patch p

04/22/2021

Vaxess is very excited to announce that we have been awarded a Commercialization Readiness Program (CRP) grant in the amount of $2.85M from the National Institute of Allergy and Infectious Diseases (NIAID)! Read the full press release here to learn more about the MIMIX sustained release technology and our upcoming plans:

Vaxess Technologies, Inc., a biotechnology company developing vaccines and therapeutics delivered through a next-generation sustained-release intrader

01/29/2021

We're excited to announce the appointment of Ted Hibben as Chief Business Officer at Vaxess. Ted will serve as an invaluable resource as Vaxess advances the MIMIX patch toward a Phase 1 proof-of-concept trial this year. Welcome to the team!

CAMBRIDGE, Mass. (PRWEB) January 29, 2021 -- Vaxess adds veteran pharma executive to leadership team to drive company strategy and facilitate partnerships

01/22/2021

Vaxess is pleased to announce that we have received funding from both the Defense Advanced Research Projects Agency - DARPA and the National Science Foundation (NSF) to develop a mRNA based, single-dose, refrigeration-free vaccine patch, in collaboration with the Santangelo Lab at Georgia Tech.

Read the full release below:

Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Free Vaccine Patch